Although the malignancy has an encouraging survival rate, it is necessary to be aware of the complexity of nasopharyngeal cancer.
Rare Cancer Series | Nasopharyngeal Cancer
Dr. Saba shares the ins and outs of nasopharyngeal carcinoma, ongoing clinical trials, and the complexities of managing the rare disease.
Nabil F. Saba, MD, FACP, discusses some of the unique characteristics of nasopharyngeal carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
2
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
3
Perioperative Pembrolizumab/Enfortumab Vedotin Approved in Europe for Cisplatin-Ineligible MIBC
4
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
5